Market revenue in 2023 | USD 205.4 million |
Market revenue in 2030 | USD 425.2 million |
Growth rate | 11% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Infectious Diseases |
Historical data | 2021 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Infectious Diseases |
Key market players worldwide | Danaher Corp, Kaneka Corp, TriLink BioTechnologies, Apex Biotechnology, BioNTech SE ADR, Lonza Group Ltd, Nunn’s Home Medical Equipment, EQT Corp, Catalent Inc, Samsung Electronics Co Ltd, Biomay AG, Indication, eTheRNA immunotherapies, BioCina |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics contract development & manufacturing market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Canada mrna therapeutics contract development & manufacturing market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
The development of mRNA therapeutics is increasing in Canada as companies are increasingly inclined toward investing in clinical trials. For instance, in June 2022, the Government of Canada announced an agreement with Moderna to produce mRNA vaccines in Canada.
This agreement began in 2021, during the COVID-19 pandemic, as the country faced intense global competition to secure vaccines. Furthermore, in February 2024, Moderna announced the completion of its mRNA vaccine production facility in Laval, Quebec.
Similarly, in October 2022, Providence Therapeutics Holdings, Inc. announced positive top-line data from the PRO-CL-002 Phase 2 study evaluating the tolerability, safety, and immunogenicity of its PTXCOVID19-B, a mRNA COVID-19 vaccine candidate. The company initiated a Phase 3 trial in a booster setting based on immunogenicity and positive safety results.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada mrna therapeutics contract development & manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Canada mrna therapeutics contract development & manufacturing market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account